CY1111264T1 - Στερεο παρασκευασμα που περιλαμβανει αλογλιπτινη και πιογλιταζονη - Google Patents

Στερεο παρασκευασμα που περιλαμβανει αλογλιπτινη και πιογλιταζονη

Info

Publication number
CY1111264T1
CY1111264T1 CY20111100150T CY111100150T CY1111264T1 CY 1111264 T1 CY1111264 T1 CY 1111264T1 CY 20111100150 T CY20111100150 T CY 20111100150T CY 111100150 T CY111100150 T CY 111100150T CY 1111264 T1 CY1111264 T1 CY 1111264T1
Authority
CY
Cyprus
Prior art keywords
pioglitazone
solid preparation
allogliptin
compound
sugar
Prior art date
Application number
CY20111100150T
Other languages
English (en)
Inventor
Kenji Nakamura
Kenichiro Kiyoshima
Junya Nomura
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39240362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111264(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of CY1111264T1 publication Critical patent/CY1111264T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Παρέχεται ένα στερεό παρασκεύασμα περιέχον την ένωση (I), όπου ο ορισμός της ενώσεως (I) είναι όπως ορίζεται στην περιγραφή, και πιογλιταζόνη, που είναι χρήσιμο ως θεραπευτικό φάρμακο για το διαβήτη και τα όμοια και ανώτερο ως προς την ιδιότητα διαλύσεως, τη χημική σταθερότητα και τη σταθερότητα διαλύσεως. Στερεό παρασκεύασμα περιέχον τα ακόλουθα πρώτο και δεύτερο μέρος: (1) το πρώτο μέρος περιέχον την ένωση (I) ή ένα άλας αυτής και, ως πρώτο έκδοχο σάκχαρο ή σακχαρούχο αλκοόλη· και (2) το δεύτερο μέρος περιέχον πιογλιταζόνη ή ένα άλας αυτής, και ως δεύτερο έκδοχο, σάκχαρο ή σακχαρούχο αλκοόλη.
CY20111100150T 2007-02-01 2011-02-09 Στερεο παρασκευασμα που περιλαμβανει αλογλιπτινη και πιογλιταζονη CY1111264T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007023594 2007-02-01
EP08704473A EP2107905B1 (en) 2007-02-01 2008-01-30 Solid preparation comprising alogliptin and pioglitazone

Publications (1)

Publication Number Publication Date
CY1111264T1 true CY1111264T1 (el) 2015-08-05

Family

ID=39240362

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100150T CY1111264T1 (el) 2007-02-01 2011-02-09 Στερεο παρασκευασμα που περιλαμβανει αλογλιπτινη και πιογλιταζονη

Country Status (39)

Country Link
US (1) US8637079B2 (el)
EP (1) EP2107905B1 (el)
JP (1) JP5284968B2 (el)
KR (1) KR101486091B1 (el)
CN (1) CN101646420B (el)
AR (1) AR065097A1 (el)
AT (1) ATE488227T1 (el)
AU (1) AU2008211981B2 (el)
BR (1) BRPI0807453B8 (el)
CA (1) CA2677201C (el)
CL (1) CL2008000279A1 (el)
CR (1) CR10992A (el)
CY (1) CY1111264T1 (el)
DE (1) DE602008003522D1 (el)
DK (1) DK2107905T3 (el)
DO (1) DOP2009000195A (el)
EA (1) EA015180B1 (el)
EC (1) ECSP099608A (el)
ES (1) ES2354397T3 (el)
GE (1) GEP20125410B (el)
HK (1) HK1138188A1 (el)
HR (1) HRP20110094T8 (el)
IL (1) IL200108A (el)
JO (1) JO2650B1 (el)
MA (1) MA31169B1 (el)
ME (1) ME01239B (el)
MX (1) MX2009008100A (el)
MY (1) MY147596A (el)
NZ (1) NZ579008A (el)
PE (1) PE20081663A1 (el)
PL (1) PL2107905T3 (el)
PT (1) PT2107905E (el)
RS (1) RS51592B (el)
SI (1) SI2107905T1 (el)
TN (1) TN2009000317A1 (el)
TW (2) TWI453041B (el)
UA (1) UA95828C2 (el)
WO (1) WO2008093882A1 (el)
ZA (1) ZA200905621B (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
ES2603879T3 (es) 2007-07-19 2017-03-01 Takeda Pharmaceutical Company Limited Preparación sólida que comprende alogliptina e hidrocloruro de metformina
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
PE20110297A1 (es) 2008-08-15 2011-05-26 Boehringer Ingelheim Int Inhibidores de dpp-4 para la cicatrizacion de heridas
KR20110067096A (ko) 2008-09-10 2011-06-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 및 관련 상태를 치료하기 위한 병용 요법
UY32126A (es) 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
WO2010092125A1 (en) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
NZ594044A (en) 2009-02-13 2014-08-29 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
BR112012012641A2 (pt) * 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
CN102883711A (zh) * 2010-05-05 2013-01-16 贝林格尔.英格海姆国际有限公司 包含吡格列酮和利格列汀的药物组合物
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
EP3366304B1 (en) 2010-06-24 2020-05-13 Boehringer Ingelheim International GmbH Diabetes therapy
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
WO2013010964A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103877054B (zh) * 2012-12-21 2016-05-25 北大方正集团有限公司 一种苯甲酸阿格列汀片剂及其制备方法
CN103156819A (zh) * 2013-03-29 2013-06-19 山东罗欣药业股份有限公司 苯甲酸阿格列汀组合物片剂及其制备方法
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
JP6027710B1 (ja) * 2014-12-25 2016-11-16 田辺三菱製薬株式会社 糖尿病治療用固形製剤
EP3310357A1 (en) * 2015-06-17 2018-04-25 H e x a l Aktiengesellschaft Alogliptin formulation
CN108289849A (zh) * 2015-06-26 2018-07-17 韩国联合制药株式会社 莫沙必利与雷贝拉唑的复合制剂
CN105030719B (zh) * 2015-08-20 2018-07-20 杭州成邦医药科技有限公司 一种含有阿格列汀和吡格列酮的组合物
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물
CN113925838B (zh) * 2021-11-11 2022-11-11 乐普制药科技有限公司 一种依帕司他与西格列汀或其可药用盐的复方缓释片及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
EP0559702B1 (de) 1990-11-27 1994-12-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Retardzubereitung für urapidil
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6030641A (en) 1997-06-03 2000-02-29 Uni Colloid Kabushiki Kaisha Sustained release capsule and method for preparing the same
JP2931811B2 (ja) 1997-06-03 1999-08-09 ユニコロイド株式会社 徐放性カプセル
DE19725911A1 (de) 1997-06-13 1998-12-17 Roland Prof Dr Bodmeier Zusammensetzungen, die die Wirkstofffreisetzung verzögern
AU8532798A (en) 1997-06-13 1998-12-30 Roland Bodmeier Compounds which delay the release of active substances
WO2000016776A1 (fr) 1998-09-18 2000-03-30 Takeda Chemical Industries, Ltd. Preparations a administrer par voie buccale a liberation lente
JP2000154137A (ja) 1998-09-18 2000-06-06 Takeda Chem Ind Ltd 徐放性経口製剤
DE60036367T2 (de) 1999-06-21 2008-05-29 Eli Lilly And Co., Indianapolis Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin-abhängigen diabetes
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
DK1741445T3 (da) 2000-01-21 2013-11-04 Novartis Ag Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
CN100367960C (zh) 2002-07-11 2008-02-13 武田药品工业株式会社 包衣制剂的制备方法
IN192749B (el) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
US7976853B2 (en) * 2003-01-29 2011-07-12 Takeda Pharmaceutical Company Limited Process for producing coated preparation
WO2005041962A1 (en) 2003-10-31 2005-05-12 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
JP4361461B2 (ja) 2003-10-31 2009-11-11 武田薬品工業株式会社 固形製剤
US20080038341A1 (en) 2004-01-20 2008-02-14 James Kowalski Direct Compression Formulation And Process
CN102134229B (zh) * 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
KR20070068407A (ko) 2004-10-25 2007-06-29 노파르티스 아게 Ｄｐｐ―ｉｖ 억제제, ｐｐａｒ 항당뇨병제 및메트포르민의 조합물
GT200600218A (es) 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
KR101352588B1 (ko) 2005-09-14 2014-01-17 다케다 야쿠힌 고교 가부시키가이샤 당뇨병 치료용 디펩티딜 펩티다아제 억제제
TW200745079A (en) 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
CA2633149C (en) 2005-12-22 2015-06-30 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
GEP20105033B (en) 2005-12-28 2010-06-25 Takeda Pharmaceuticals Co Therapeutic agent for diabetes

Also Published As

Publication number Publication date
JP2010517937A (ja) 2010-05-27
MY147596A (en) 2012-12-31
IL200108A0 (en) 2010-04-15
EA015180B1 (ru) 2011-06-30
BRPI0807453B8 (pt) 2021-05-25
TWI453041B (zh) 2014-09-21
KR101486091B1 (ko) 2015-01-23
CA2677201A1 (en) 2008-08-07
PL2107905T3 (pl) 2011-04-29
MX2009008100A (es) 2009-08-07
US8637079B2 (en) 2014-01-28
MA31169B1 (fr) 2010-02-01
US20100092551A1 (en) 2010-04-15
IL200108A (en) 2012-02-29
BRPI0807453B1 (pt) 2021-01-05
DK2107905T3 (da) 2011-01-31
PE20081663A1 (es) 2008-12-25
CN101646420A (zh) 2010-02-10
AU2008211981B2 (en) 2012-09-20
GEP20125410B (en) 2012-02-27
TW201350143A (zh) 2013-12-16
ATE488227T1 (de) 2010-12-15
HK1138188A1 (en) 2010-08-20
ES2354397T3 (es) 2011-03-14
SI2107905T1 (sl) 2011-03-31
DOP2009000195A (es) 2009-08-31
ZA200905621B (en) 2010-10-27
NZ579008A (en) 2012-02-24
JP5284968B2 (ja) 2013-09-11
JO2650B1 (en) 2012-06-17
UA95828C2 (ru) 2011-09-12
CA2677201C (en) 2015-11-17
CL2008000279A1 (es) 2008-08-18
ECSP099608A (es) 2009-09-29
BRPI0807453A2 (pt) 2014-05-20
EP2107905B1 (en) 2010-11-17
AR065097A1 (es) 2009-05-13
ME01239B (me) 2013-06-20
TN2009000317A1 (en) 2010-12-31
HRP20110094T1 (hr) 2011-03-31
DE602008003522D1 (de) 2010-12-30
EP2107905A1 (en) 2009-10-14
EA200970726A1 (ru) 2010-02-26
HRP20110094T8 (en) 2011-07-31
RS51592B (en) 2011-08-31
CR10992A (es) 2009-09-16
TW200836775A (en) 2008-09-16
CN101646420B (zh) 2012-11-07
KR20090109115A (ko) 2009-10-19
AU2008211981A1 (en) 2008-08-07
PT2107905E (pt) 2010-12-17
WO2008093882A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
CY1111264T1 (el) Στερεο παρασκευασμα που περιλαμβανει αλογλιπτινη και πιογλιταζονη
CY1112921T1 (el) Ενεργοποιητες γλυκοκινασης πυρρολιδινονης
CY1126112T1 (el) Φαρμακοτεχνικες μορφες που περιεχουν ενυδρη προπυλενογλυκολη δαπαγλιφλοζινης
CY1116150T1 (el) Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
EA201170527A1 (ru) Фармацевтические композиции, включающие соединения бороновой кислоты
CY1117615T1 (el) Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης
CY1114793T1 (el) Παραγωγα αμινοπυραζολιου
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
CO6511251A2 (es) Compuestos quimicos
EA200501095A1 (ru) Фенилацетамиды и их применение в качестве модуляторов глюкокиназы
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
CY1117176T1 (el) Στερεο παρασκευασμα το οποιο περιλαμβανει πιογλιταζονη, γλιμεπιριδη και εναν εστερα λιπαρου οξεος πολυοξυαιθυλενο σορβιτανης
CY1110332T1 (el) Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους
WO2008002244A3 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
CY1111903T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου με αναλγητικη δραση
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
CY1111442T1 (el) Ενωσεις πιπεριδινης και χρησεις αυτων
DK1885187T3 (da) Fremgangsmåde til behandling af lægemiddelresistent cancer
EA201001859A1 (ru) Гетероциклические производные мочевины и способы их применеия
CY1109376T1 (el) Παραγωγα υδαντοϊνης χρησιμα ως αναστολεις μεταλλοπρωτεϊνασης
EA201001858A1 (ru) Гетероциклические производные мочевины для лечения бактериальных инфекций
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
SE0302546D0 (sv) New compounds
WO2010080414A3 (en) Substituted fno (2-[furan-2-yl] naphthalen-1-ol) derivatives as anti-cancer agents